The Effect of a Multispecies Probiotic on Hypersensitivity in Irritable Bowel Syndrome (IBS) Patients

Maastricht University Medical Centre (MUMC)

Status

Completed

Conditions

Irritable Bowel Syndrome

Hypersensitivity

Treatments

Dietary Supplement: multispecies probiotic (Ecologic 801)

Dietary Supplement: Placebo

Study type

Interventional

Funder types

Other

Industry

Identifiers

NCT00702026

MEC 08-1-031

Details and patient eligibility

About

The purpose of this study is to determine whether a specifically designed multispecies probiotic decreases visceral hypersensitivity in IBS-patient (defined by an increased pain tolerance threshold). Moreover, the effect on general symptom scores and inflammatory and microbiological parameters will be studied.

Enrollment

40 patients

Sex

All

Ages

18 to 65 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Clinical diagnosis of IBS according to the Rome III criteria
Increased visceral perception according to barostat measurements, defined as a pain tolerance threshold at smaller than or equal to 23 mmHg
Age between 18 and 65 years
BMI between 18.5 and 30 kg/m2

Exclusion criteria

Known gastro-intestinal diseases
Major abdominal surgery
Previous radiotherapy, chemotherapy
Clinical significant systemic diseases
Critically ill patients or patients suffering from severe acute pancreatitis
Patients with organs failure
Patients receiving enteral feeding
Excessive alcohol intake (greater than 15 consumptions per week)
(planned) pregnancy or lactation
Use of pre-, probiotics in the month before and during the study
Use of antibiotics in the two months before and during the study
Use of anti-diarrhoea medication, anti-laxatives or anti-acid medication in the two weeks before and during the study
Use of anti depressives (especially SSRI's) in the month before and during the study
Use of other medication if less then one month on stable dosage